StartseiteMCPWorkbenchSkills
StartseiteWorkbenchBenachrichtigungenMein Bereich
llms.txt · MCP-AnleitungDatenschutz · Nutzungsbedingungen · Supportv1.8.3
  1. Startseite
  2. /Verbindung

Lacosamide

HCID 219078
Neue Reaktion
Drucken
GrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung
TeilstruktursucheÄhnliche Strukturen suchen

Grundinformationen

CAS
175481-36-4
Standard-SMILES
COC[C@@H](NC(C)=O)C(=O)NCc1ccccc1
InChIKey
VPPJLAIAVCUEMN-GFCCVEGCSA-N
Summenformel
C13H18N2O3
Durchschnittliche Molmasse
250,29 g/mol
Monoisotopische Masse
250,13174244

Überblick

Lacosamide is a N-acyl-amino acid.

Namen und Bezeichner

Bevorzugter Name
Lacosamide
IUPAC
(2R)-2-acetamido-N-benzyl-3-methoxypropanamide
Englischer Name
Lacosamide
Summenformel
C13H18N2O3
Molmasse
250.29

Namen und Synonyme

Lacosamide175481-36-4ErlosamideVimpatHarkoserideSPM 927SPM-927(r)-lacosamide 1MOTPOLYLacosamidaDTXSID1057666ADD 234037
Weitere Namen anzeigen
Lacosamide API(R)-2-Acetamido-N-benzyl-3-methoxypropanamide(2R)-2-acetamido-N-benzyl-3-methoxy-propanamideACOSAMIDEADD 243037Lacoxamide
563KS2PQY5SPM927Propanamide, 2-(acetylamino)-3-methoxy-N-(phenylmethyl)-, (2R)-ADD243037ADD-243037(2R)-2-(Acetylamino)-N-benzyl-3-methoxypropanamide(2R)-2-(Acetylamino)-3-methoxy-N-(phenylmethyl)propanamideDTXCID2031455

Datenbank-Bezeichner

CAS
175481-36-4
PubChem CID
219078
DTXSID
DTXSID1057666
ChEMBL
CHEMBL58323
ChEBI
CHEBI:135939
UNII
563KS2PQY5
EC Number
605-756-0
Nikkaji
J1.029.117H

Eigenschaften

Berechnete Struktureigenschaften

XLogP
0,3
Polarare Oberfläche (TPSA)
67,4 Ų
H-Brücken-Donoren
2
H-Brücken-Akzeptoren
3
Frei drehbare Bindungen
6
Schwere Atome
18
Formalladung
0
Komplexität
275

Experimentelle und physikochemische Eigenschaften

Drugs · 5 Einträge

DEA Schedule V Controlled Substance -> Depressants

Pharmaceuticals -> Listed in ZINC15

Pharmaceuticals -> Used in Switzerland

Pharmaceuticals -> Synthetic Cannabinoids or Psychoactive Compounds

Pharmaceuticals -> Antiepileptic

Solubility10-33.3 g/L
Human Drugs · 6 Einträge

Breast Feeding; Lactation; Milk, Human; Anticonvulsants

FDA approved drugs -> Active ingredient

EMA approved medicines: Human medicine

EMA approved medicines: Human medicine

EMA approved medicines: Human medicine

EMA approved medicines: Human medicine

Melting Point140-146˚C

Physikochemische Eigenschaften

Schmelzpunkt
141 · 141-143C
Siedepunkt
536.4 · 536.4±50.0 °C(Predicted)
Dichte
1.12 · 1.120±0.06 g/cm3(Predicted)
Flammpunkt

Sicherheit und Regulatorisches

Sicherheitsangaben dienen nur zur Orientierung und ersetzen weder das Sicherheitsdatenblatt (SDB) des Lieferanten noch geltende Vorschriften oder eine fachliche Bewertung.

GHS-Klassifizierung

GHS Classification · 5 Einträge

This chemical does not meet GHS hazard criteria for 1.5% (1 of 66) of reports.

Danger

H301 (93.9%): Toxic if swallowed [Danger Acute toxicity, oral]

P264, P264+P265, P270, P280, P301+P316, P305+P351+P338, P321, P330, P337+P317, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 66 reports by companies from 8 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

Gefahrenhinweise

Regulatory InformationDEA schedule V controlled substance
Hazard Classes and CategoriesAcute Tox. 3 (93.9%)

Toxikologische Informationen

Hepatotoxicity · 1 Eintrag

In prelicensure clinical trials, addition of lacosamide to standard anticonvulsant therapy was reported to be associated with ALT elevations above 3 times the upper limit of normal (ULN) in 7 of 935 patients (0.7%) compared to none of 356 treated with placebo. A single case of hepatitis with jaundice during lacosamide therapy was also reported. Since approval, there have been rare isolated reports of clinically apparent liver injury associated with lacosamide used, but the clinical features suggested that hepatic ischemia or other anticonvulsants combined with lacosamide may have been responsible. The onset was within a few days to several months after starting and the presentation was with a hepatocellular pattern of serum enzyme elevations, one case being asymptomatic and mild and the other severe. In both instances, there was rapid recovery.

Drug Induced Liver Injury

Chemie und Industrie

Pharmakologische Informationen

ATC Code · 3 Einträge

N03AX18

N - Nervous system

QN - Nervous system

Protein BindingLacosamide is less than 15% bound to plasma proteins.
Pharmacodynamics · 1 Eintrag

Lacosamide is an antiepileptic drug with high oral potency, stereoselectivity, and anticonvulsant effects. By blocking sensory neuronal voltage-gated sodium channels that mediate neuropathic pain responses, lacosamide was shown to possess analgesic activity. Lacosamide is a chiral functionalized amino acid. The S-stereoisomer does not exhibit antiepileptic activity.

Mechanism of Action · 1 Eintrag

Caused by neuronal hyperexcitability, seizures in epilepsy involve sustained firing of sodium-dependent action potentials. The slow inactivation process, intrinsic to voltage-gated sodium channel functioning, has been implicated in the paroxysmal depolarizing shifts associated with epileptic activity. The exact mechanism of action of lacosamide is not fully known; however, in vitro electrophysiological studies have shown that lacosamide selectively enhances the slow inactivation of voltage-gated sodium channels, shifting the slow inactivation curve to more hyperpolarized potentials and augmenting the maximal fraction of channels in the slow inactivated state. This results in the stabilization of hyperexcitable neuronal membranes and inhibition of repetitive neuronal firing. Lacosamide does not affect the fast component of voltage-gated sodium currents, unlike traditional sodium channel blockers.

Biological Half-Life · 1 Eintrag

The elimination half-life of the unchanged drug is approximately 13 hours and is not altered by different doses, multiple dosing or intravenous administration. The major O-desmethyl metabolite of lacosamide has an elimination half-life ranging from 15 to 23 hours).

Metabolism/MetabolitesLacosamide is metabolized by CYP3A4, CYP2C9, and CYP2C19 to form O-desmethyl lacosamide, which is a major, pharmacologically inactive metabolite in humans. There is no enantiomeric interconversion of lacosamide.

Zugehörige Reaktionen

19
Reaktionsaufzeichnung erstellen
Reaktionsgleichung von HRID 62571
HRID 62571als Edukt
Reaktionsgleichung von HRID 62578
HRID 62578als Produkt
Reaktionsgleichung von HRID 389387
HRID 389387als Produkt
Reaktionsgleichung von HRID 389388
HRID 389388als Produkt
Reaktionsgleichung von HRID 410135
HRID 410135als Produkt
Reaktionsgleichung von HRID 420115
HRID 420115als Produkt
Reaktionsgleichung von HRID 420116
HRID 420116als Produkt
Reaktionsgleichung von HRID 534694
HRID 534694als Produkt
ZurückSeite 1 von 3

Notizen zur Verbindung

Auf dieser SeiteGrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung
2 ℃ · 2℃
storage temp.
Refrigerator
Löslichkeit
20 mg/ml; · DMF: 20 mg/ml; DMSO: 20 mg/ml; Ethanol: 20 mg/ml; PBS (pH 7.2): 2 mg/ml
Aggregatzustand
A crystalline solid
pka
14.19 · 14.19±0.46(Predicted)
Farbe
white to beige
InChI
InChI=1S/C13H18N2O3/c1-10(16)15-12(9-18-2)13(17)14-8-11-6-4-3-5-7-11/h3-7,12H,8-9H2,1-2H3,(H,14,17)(H,15,16)/t12-/m1/s1
InChIKey
VPPJLAIAVCUEMN-GFCCVEGCSA-N
SMILES
C(NCC1=CC=CC=C1)(=O)[C@H](NC(C)=O)COC
CAS Datenbank
175481 · 175481-36-4
· 6 Einträge

Drug Induced Liver Injury Rank (DILIrank 2.0)

Lacosamide

Ambiguous-DILI-concern

3

Warnings & precautions

DOI:10.1016/j.drudis.2016.02.015

Effects During Pregnancy and Lactation◉ Summary of Use during Lactation

Sicherheitsdaten

wgk
2
ridadr
UN 1648 3 / PGII
hs_code
2924296000
risk_code
11-20/21/22-36
hazard_code
F,Xn
safety_code
16-26-36/37
Speicherklasse
11 - Combustible Solids
Hazard Classifications
Acute Tox. 4 Oral
FDA Pharmacological Classification · 6 Einträge

563KS2PQY5

LACOSAMIDE

Physiologic Effects [PE] - Decreased Central Nervous System Disorganized Electrical Activity

The physiologic effect of lacosamide is by means of Decreased Central Nervous System Disorganized Electrical Activity.

LACOSAMIDE

Decreased Central Nervous System Disorganized Electrical Activity [PE]

MeSH Pharmacological Classification · 2 Einträge

Drugs used to prevent SEIZURES or reduce their severity.

A class of drugs that inhibit the activation of VOLTAGE-GATED SODIUM CHANNELS.

Absorption, Distribution and Excretion · 3 Einträge

Lacosamide is completely absorbed after oral administration with negligible first-pass effect. It has a high absolute bioavailability of approximately 100%. Food does not affect the rate and extent of absorption. The Tmax ranges from one to four hours. Steady-state plasma concentrations are achieved after three days of twice-daily repeated administration. The pharmacokinetics of lacosamide are dose-proportional over the dose range between 100 and 800 mg, and time-invariant, with low inter- and intra-subject variability. The major O-desmethyl metabolite of lacosamide has a longer Tmax that ranges from 0.5 to 12 hours. After intravenous administration, Cmax is reached at the end of infusion. The 30- and 60-minute intravenous infusions are bioequivalent to the oral tablet. For the 15-minute intravenous infusion, bioequivalence was met for AUC0-tz but not for Cmax. The point estimate of Cmax was 20% higher than Cmax for oral tablet and the 90% CI for Cmax exceeded the upper boundary of the bioequivalence range. In a trial comparing the oral tablet with an oral solution containing 10 mg/mL lacosamide, bioequivalence between both formulations was shown. A single loading dose of 200 mg approximates steady-state concentrations comparable to the 100 mg twice-daily oral administration.

Lacosamide is primarily eliminated from the systemic circulation by renal excretion and biotransformation. After oral and intravenous administration of 100 mg radiolabeled lacosamide, approximately 95% of the radioactivity was recovered in the urine and less than 0.5 % in the feces. The major compounds excreted were unchanged lacosamide (approximately 40% of the dose), its O-desmethyl metabolite (approximately 30%), and a structurally unknown polar fraction (~20%).

The volume of distribution is approximately 0.6 L/kg and thus close to the volume of total body water.

Verwendung und Herstellung

UsesUse (kg; approx.) in Germany (2009): >250
Anwendungen · 3 Einträge

BeschreibungAlthough epilepsy is a neurological disorder with varying etiology and severity, the common feature is unprovoked, recurring seizures. Whether classified as generalized, involving both cerebral hemispheres, or partial with only localized portions of brain participation at onset, effective treatment relies on accurate assessment of syndrome type to optimally decrease the frequency, duration, and severity of seizures. The latest weapon against partial onset epilepsy is lacosamide, formerly known as harkoseride and erlosamide. The data also indicate that lacosamide binds to collapsing response mediator protein 2 (CRMP2); CRMP2 is involved in neuronal differentiation, control of axonal outgrowth, and possibly epileptogenesis. Furthermore, lacosamide is heralded as having a dual mode of action as it has also displayed efficacy against diabetic neuropathy, possibly as a result of stabilization of neuronal hyperexcitability. Currently,lacosamide is approved as adjunctive treatment of partial onset seizures in patients 17 years or older and is in development as a monotherapy for epilepsy and for neuropathic pain.

HistoryLacosamide, a functionalized amino acid, has become an important third-generation antiepileptic drug after systematic drug development. Its discovery stemmed from a 1996 study at the University of Houston, where researchers hypothesized that modified amino acids might have potential applications in epilepsy treatment. Against this backdrop, Dr. Harold Cohen and his team, while studying the mechanism of action of biotin, noticed its structural similarity to certain neuroactive compounds, inspiring them to synthesize a series of functionalized amino acids and screen for their anticonvulsant activity. With the support of the National Institute of Neurological Diseases and Stroke (NINDS) anticonvulsant drug screening program, lacosamide (then codenamed SPM 927) was identified as a promising candidate drug due to its potent anticonvulsant properties.In 2000, Schwarz Pharma in Germany collaborated with Harris FRC to advance the preclinical and clinical development of lacosamide. Based on substantial clinical evidence, lacosamide's marketing application was approved by the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) in 2007. In September 2008, the drug was officially approved for marketing in the European Union, and in October of the same year, it was approved in the United States under the brand name Vimpat®. In November 2018, lacosamide tablets were approved for marketing in China, becoming the first third-generation antiepileptic drug approved in China. Subsequently, oral solutions and other dosage forms were also launched. To date, the clinical application of lacosamide has expanded from its initial role as adjunctive therapy for adult partial epilepsy to monotherapy, and is used to treat a wider range of pediatric patients and primary generalized tonic-clonic epilepsy.

VerwendenA potent anticonvulsant.